$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

$arwr Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000162828023040219 Filed on November 29, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023
Revenue	$3.551M	$16.10M	$240.7M
YoY Change	-94.32%	-49.02%	-1.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$26.19M	$26.78M	$101.3M
YoY Change	15.61%	-15.31%	-22.13%
% of Gross Profit
Research & Development	$116.5M	$93.79M	$353.2M
YoY Change	39.19%	15.61%	18.8%
% of Gross Profit
Depreciation & Amortization	$3.800M	$3.893M	$10.70M
YoY Change	65.22%	46.35%	22.99%
% of Gross Profit
Operating Expenses	$140.1M	$124.4M	$445.7M
YoY Change	33.83%	7.82%	5.69%
Operating Profit	-$136.5M		-$205.0M
YoY Change	224.07%		14.84%
Interest Expense	$5.367M	-$1.377M	$18.33M
YoY Change	-3313.77%	-186.99%	264.12%
% of Operating Profit
Other Income/Expense, Net	-$2.144M	$717.0K	-$1.489M
YoY Change	-730.59%	696.67%	-125.68%
Pretax Income	-$138.7M	-$109.0M	-$206.5M
YoY Change	231.84%	32.66%	19.56%
Income Tax	-$3.300M	$2.025M	$2.784M
% Of Pretax Income
Net Earnings	-$132.9M	-$109.7M	-$205.3M
YoY Change	221.51%	28.26%	16.59%
Net Earnings / Revenue	-3741.59%	-681.36%	-85.27%
Basic Earnings Per Share	-$1.24		-$1.92
Diluted Earnings Per Share	-$1.24	-$1.02	-$1.92
COMMON SHARES
Basic Shares Outstanding	107.4M shares	107.2M shares	106.8M shares
Diluted Shares Outstanding	107.4M shares		106.8M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$220.3M	$403.6M	$395.7M
YoY Change	-56.11%	7.23%	5.13%
Cash & Equivalents	$58.20M	$110.9M	$103.0M
Short-Term Investments	$162.1M	$292.7M	$292.7M
Other Short-Term Assets	$7.104M	$7.082M	$23.80M
YoY Change	-71.8%	-64.95%	-13.43%
Inventory
Prepaid Expenses	$10.52M	$8.813M
Receivables		$0.00	$0.00
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$237.9M	$419.5M	$419.5M
YoY Change	-58.63%	3.51%	3.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$333.4M	$290.3M	$335.6M
YoY Change	126.33%	163.16%	99.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$232.0K	$210.0K	$200.0K
YoY Change	10.48%	-3.67%	-8.26%
Total Long-Term Assets	$388.4M	$346.0M	$346.1M
YoY Change	22.72%	20.72%	20.74%
TOTAL ASSETS
Total Short-Term Assets	$237.9M	$419.5M	$419.5M
Total Long-Term Assets	$388.4M	$346.0M	$346.1M
Total Assets	$626.3M	$765.6M	$765.6M
YoY Change	-29.75%	10.64%	10.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.460M	$35.87M	$35.90M
YoY Change	460.3%	1150.56%	1151.74%
Accrued Expenses	$46.60M	$39.76M	$68.30M
YoY Change	-3.26%	-15.14%	10.37%
Deferred Revenue	$0.00	$866.0K
YoY Change	-100.0%	-98.83%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$63.72M	$105.5M	$105.5M
YoY Change	-47.77%	-24.05%	-24.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$388.8M	$372.9M	$372.9M
YoY Change	4.22%	176.76%	176.73%
Total Long-Term Liabilities	$388.8M	$372.9M	$372.9M
YoY Change	4.22%	176.76%	176.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$63.72M	$105.5M	$105.5M
Total Long-Term Liabilities	$388.8M	$372.9M	$372.9M
Total Liabilities	$452.6M	$478.4M	$494.2M
YoY Change	-8.59%	74.85%	68.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.159B	-$1.026B
YoY Change	34.43%	25.01%
Common Stock	$1.321B	$1.301B
YoY Change	6.55%	6.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$160.4M	$271.3M	$271.3M
YoY Change
Total Liabilities & Shareholders Equity	$626.3M	$765.6M	$765.6M
YoY Change	-29.75%	10.64%	10.65%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$132.9M	-$109.7M	-$205.3M
YoY Change	221.51%	28.26%	16.59%
Depreciation, Depletion And Amortization	$3.800M	$3.893M	$10.70M
YoY Change	65.22%	46.35%	22.99%
Cash From Operating Activities	-$117.8M	-$25.29M	-$153.9M
YoY Change	56.05%	-63.17%	13.05%
INVESTING ACTIVITIES
Capital Expenditures	$68.66M	$63.94M	$176.7M
YoY Change	76.44%	-295.46%	234.88%
Acquisitions
YoY Change
Other Investing Activities	$133.5M	$94.38M	$80.60M
YoY Change	-419.5%	36.48%	70.19%
Cash From Investing Activities	$64.84M	$30.55M	-$96.16M
YoY Change	-180.35%	-16.19%	1675.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$267.0K	153.0K	$253.1M
YoY Change	-99.89%	-82.11%	288.2%
NET CHANGE
Cash From Operating Activities	-$117.8M	-25.29M	-$153.9M
Cash From Investing Activities	$64.84M	30.55M	-$96.16M
Cash From Financing Activities	$267.0K	153.0K	$253.1M
Net Change In Cash	-$52.73M	5.408M	$3.008M
YoY Change	-155.88%	-117.24%	-103.94%
FREE CASH FLOW
Cash From Operating Activities	-$117.8M	-$25.29M	-$153.9M
Capital Expenditures	$68.66M	$63.94M	$176.7M
Free Cash Flow	-$186.5M	-$89.23M	-$330.6M
YoY Change	62.98%	148.16%	75.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	110297000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10262000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11962000	usd
CY2023Q3	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	0	usd
CY2022Q3	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	105872000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45297000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58291000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	210000	usd
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	468
CY2023	dei	Auditor Name AuditorName	Rose, Snyder & Jacobs LLP
CY2023	dei	Auditor Location AuditorLocation	Encino, California
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110891000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108005000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1410000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	292735000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2023Q3	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	0	usd
CY2022Q3	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	268391000	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8813000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7289000	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	7082000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	20204000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	419521000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	405299000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290262000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	218000	usd
CY2023Q3	us-gaap	Assets Assets	765552000	usd
CY2022Q3	us-gaap	Assets Assets	691939000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	35866000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2868000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39763000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46856000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17963000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12251000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10563000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2776000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	866000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	74099000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	435000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	105456000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	138850000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	104608000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	78800000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	55950000	usd
CY2023Q3	arwr	Royalties Liability Noncurrent RoyaltiesLiabilityNoncurrent	268326000	usd
CY2022Q3	arwr	Royalties Liability Noncurrent RoyaltiesLiabilityNoncurrent	0	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	372934000	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	134750000	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107312000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107312000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	105960000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	105960000	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	200000	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	198000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1300395000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1219213000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3222000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-136000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1026030000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-820755000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	271343000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	398520000	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	15819000	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	19819000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	287162000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	418339000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	765552000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	691939000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	240735000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	243231000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	138287000	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	353188000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	297307000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	206342000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	92549000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	124431000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	80981000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	445737000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	421738000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	287323000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-87000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-140848000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	408822000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	408822000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	120893000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-205002000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-178507000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-149036000	usd
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	15299000	usd
CY2022	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	5033000	usd
CY2021	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	6120000	usd
CY2023	us-gaap	Interest Expense InterestExpense	18326000	usd
CY2022	us-gaap	Interest Expense InterestExpense	0	usd
CY2021	us-gaap	Interest Expense InterestExpense	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1538000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	765000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2070000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1489000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5798000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8190000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-206491000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-172709000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-140846000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2784000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3785000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-209275000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-176494000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-140848000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4000000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-431000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-205275000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-176063000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-140848000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.92
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.67
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.36
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.92
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.67
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.36
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106750000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105426000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103745000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106750000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105426000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103745000	shares
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-122000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-67000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-87000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-212361000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-176561000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-140935000	usd
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	461779000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	76673000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11305000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	295699000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5185000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-67000	usd
CY2022	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	60000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-176494000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	418339000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	418339000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	78130000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3054000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2964000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-122000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	287162000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-209275000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-176494000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-140848000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	78130000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	120893000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	76673000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12493000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10421000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8267000	usd
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	2017000	usd
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-2910000	usd
CY2021	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-266000	usd
CY2023	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	18326000	usd
CY2022	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	0	usd
CY2021	arwr	Non Cash Interest Expense Liability Related To Sale Of Future Royalties NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties	0	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-4432000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	1708000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1410000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8845000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9409000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11603000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19291000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	360000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	32998000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6589000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2628000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-14965000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	17750000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	9522000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-129183000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-112501000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	223258000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	46590000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	13428000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	3192000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	65000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-169000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-153890000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-136131000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	171312000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	176737000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	52777000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23567000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	246141000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	223391000	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	240703000	usd
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	326723000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	270751000	usd
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	122592000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-96155000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5417000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-141678000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3053000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5186000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11305000	usd
CY2023	arwr	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	250000000	usd
CY2022	arwr	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	0	usd
CY2021	arwr	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	0	usd
CY2023	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0	usd
CY2022	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	60000000	usd
CY2021	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	253053000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	65186000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11305000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3008000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-76362000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	40939000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-122000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-67000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-88000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108005000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184434000	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143583000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	122300000	usd
CY2023Q3	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent	0	usd
CY2023Q3	arwr	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent	2964000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	292735000	usd
CY2023Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	295700000	usd
CY2023	us-gaap	Other Comprehensive Income Reclassification Adjustment For Held To Maturity Transferred To Available For Sale Securities Before Tax OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax	-3000000	usd
CY2022Q3	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	268391000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110900000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	7900000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	292700000	usd
CY2023	arwr	Increase Decrease In Cash And Investments IncreaseDecreaseInCashAndInvestments	-78600000	usd
CY2023Q3	arwr	Development Regulatory And Sales Milestones Payments DevelopmentRegulatoryAndSalesMilestonesPayments	2800000000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	7900000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	7300000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentration of Credit Risk</span></div>Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash, cash equivalents and restricted cash and investments. As of September 30, 2023 and 2022, the Company’s investments were primarily invested in money market funds, certificates of deposit, commercial paper, and corporate debt securities through highly rated financial institutions. The Company also maintains several bank accounts primarily at three financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022Q3	arwr	Debt Securities Held To Maturity Accumulated Unrecognized Gain Current DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent	0	usd
CY2022Q3	arwr	Debt Securities Held To Maturity Accumulated Unrecognized Loss Current DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent	3661000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	240735000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	243231000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	138287000	usd
CY2023Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2022Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	1410000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	866000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	130049000	usd
CY2023Q3	arwr	Computers Software Office Equipment And Furniture Gross ComputersSoftwareOfficeEquipmentAndFurnitureGross	2240000	usd
CY2022Q3	arwr	Computers Software Office Equipment And Furniture Gross ComputersSoftwareOfficeEquipmentAndFurnitureGross	2182000	usd
CY2023Q3	us-gaap	Land Land	2996000	usd
CY2022Q3	us-gaap	Land Land	2996000	usd
CY2023Q3	arwr	Research Equipment Gross ResearchEquipmentGross	56509000	usd
CY2022Q3	arwr	Research Equipment Gross ResearchEquipmentGross	38283000	usd
CY2023Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	103813000	usd
CY2022Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	42017000	usd
CY2023Q3	us-gaap	Construction In Progress Gross ConstructionInProgressGross	166655000	usd
CY2022Q3	us-gaap	Construction In Progress Gross ConstructionInProgressGross	56373000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	332213000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	141851000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41951000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31554000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290262000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	110297000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10700000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8700000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6600000	usd
CY2022Q3	us-gaap	Debt Securities Held To Maturity Fair Value Current DebtSecuritiesHeldToMaturityFairValueCurrent	264730000	usd
CY2022Q3	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	105872000	usd
CY2022Q3	arwr	Debt Securities Held To Maturity Accumulated Unrecognized Gain Noncurrent DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent	0	usd
CY2022Q3	arwr	Debt Securities Held To Maturity Accumulated Unrecognized Loss Noncurrent DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent	5569000	usd
CY2022Q3	us-gaap	Debt Securities Held To Maturity Fair Value Noncurrent DebtSecuritiesHeldToMaturityFairValueNoncurrent	100303000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1700000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1700000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1700000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1700000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1700000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1762000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10262000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107312000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107312000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	145000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	105960000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	105960000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	145000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	290000000	shares
CY2023Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2022Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2021Q4	arwr	Tax Increment Financing Award TaxIncrementFinancingAward	16000000	usd
CY2021Q4	arwr	Tax Increment Financing Award Maximum State Income Tax Credits Under Agreement TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement	2500000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1500000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58291000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2776000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	78800000	usd
CY2021	us-gaap	Lease Cost LeaseCost	5962000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10735000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	15000000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	15341000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	14514000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	13156000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	124951000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	193697000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	78526000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	115171000	usd
CY2021	arwr	Operating Lease Cash Received For Amounts Included In Measurement Of Lease Liabilities OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	17071000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3100000	usd
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	6204720	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2263477	shares
CY2023Q3	arwr	Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding	6505117	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2721384	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.73
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	32151	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	33.03
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	50708	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	60.72
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	439350	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.94
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2263477	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y3M18D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	26795879	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2141592	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	21.45
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y2M12D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	26786757	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0369
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0457
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0040
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.011
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.864
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.862
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.904
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	25.61
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	48.64
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-194639000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-170570000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-140846000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7852000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1708000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-202491000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-172278000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-140846000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1074000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1710000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	304000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3481000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2784000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3785000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2784000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3785000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.086
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.070
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.068
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.046
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.017
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2023	arwr	Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent	-0.046
CY2022	arwr	Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent	0
CY2021	arwr	Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0.012
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Fdii Percent EffectiveIncomeTaxRateReconciliationFdiiPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.011
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.017
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.013
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.205
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.284
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.293
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.014
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.022
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	60495000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	171319000	usd
CY2023Q3	arwr	Deferred Tax Assets In Process Research And Development Cost DeferredTaxAssetsInProcessResearchAndDevelopmentCost	75208000	usd
CY2022Q3	arwr	Deferred Tax Assets In Process Research And Development Cost DeferredTaxAssetsInProcessResearchAndDevelopmentCost	324000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	66407000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	0	usd
CY2023Q3	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	59441000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	38810000	usd
CY2023Q3	arwr	Deferred Tax Assets Right Of Use Assets Or Lease Liabilities DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities	25382000	usd
CY2022Q3	arwr	Deferred Tax Assets Right Of Use Assets Or Lease Liabilities DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities	2844000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10296000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	41479000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3082000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2961000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1523000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2973000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2636000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2162000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	304470000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	262872000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	284626000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	242394000	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	9878000	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1088000	usd
CY2023Q3	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	9966000	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	usd
CY2023Q3	arwr	Deferred Tax Liabilities State Taxes DeferredTaxLiabilitiesStateTaxes	0	usd
CY2022Q3	arwr	Deferred Tax Liabilities State Taxes DeferredTaxLiabilitiesStateTaxes	19390000	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	19844000	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	20478000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	284600000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	242400000	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3481000	usd
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2020Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	9495000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3481000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1489000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3049000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	3500000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	600000	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	900000	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3500000	usd
CY2023Q3	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	3500000	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2200000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1700000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1300000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-205275000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-176063000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-140848000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106750000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105426000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103745000	shares
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106750000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105426000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103745000	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.92
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.67
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.36
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.92
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.67
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.36
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4053000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3885000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2063000	shares

Files In Submission

Name	View Source	Status
arwr-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001628280-23-040219-index-headers.html	Edgar Link	pending
0001628280-23-040219-index.html	Edgar Link	pending
0001628280-23-040219.txt	Edgar Link	pending
0001628280-23-040219-xbrl.zip	Edgar Link	pending
a1011-arrowhead_2021plan.htm	Edgar Link	pending
a1011-arrowhead_2021plan001.jpg	Edgar Link	pending
a1011-arrowhead_2021plan002.jpg	Edgar Link	pending
a1011-arrowhead_2021plan003.jpg	Edgar Link	pending
a1011-arrowhead_2021plan004.jpg	Edgar Link	pending
a1011-arrowhead_2021plan005.jpg	Edgar Link	pending
a1011-arrowhead_2021plan006.jpg	Edgar Link	pending
a1039-firstamendmenttole.htm	Edgar Link	pending
a1039-firstamendmenttole001.jpg	Edgar Link	pending
a1039-firstamendmenttole002.jpg	Edgar Link	pending
a1039-firstamendmenttole003.jpg	Edgar Link	pending
a107-2021formofrsuoffice.htm	Edgar Link	pending
a107-2021formofrsuoffice001.jpg	Edgar Link	pending
a107-2021formofrsuoffice002.jpg	Edgar Link	pending
a107-2021formofrsuoffice003.jpg	Edgar Link	pending
a107-2021formofrsuoffice004.jpg	Edgar Link	pending
a109-2021formrsuawardemp.htm	Edgar Link	pending
a109-2021formrsuawardemp001.jpg	Edgar Link	pending
a109-2021formrsuawardemp002.jpg	Edgar Link	pending
a109-2021formrsuawardemp003.jpg	Edgar Link	pending
a109-2021formrsuawardemp004.jpg	Edgar Link	pending
a97-arwrxclawbackpolicyf.htm	Edgar Link	pending
a97-arwrxclawbackpolicyf001.jpg	Edgar Link	pending
a97-arwrxclawbackpolicyf002.jpg	Edgar Link	pending
a97-arwrxclawbackpolicyf003.jpg	Edgar Link	pending
arwr-20230930.htm	Edgar Link	pending
arwr-20230930.xsd	Edgar Link	pending
arwr-20230930xex231.htm	Edgar Link	pending
arwr-20230930xex311.htm	Edgar Link	pending
arwr-20230930xex311001.jpg	Edgar Link	pending
arwr-20230930xex312.htm	Edgar Link	pending
arwr-20230930xex312001.jpg	Edgar Link	pending
arwr-20230930xex321.htm	Edgar Link	pending
arwr-20230930xex321001.jpg	Edgar Link	pending
arwr-20230930xex322.htm	Edgar Link	pending
arwr-20230930xex322001.jpg	Edgar Link	pending
arwr-20230930_g1.gif	Edgar Link	pending
arwr-20230930_g2.jpg	Edgar Link	pending
arwr-20230930_g3.jpg	Edgar Link	pending
arwr-20230930_g4.gif	Edgar Link	pending
arwr-20230930_g5.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
arwr-20230930_def.xml	Edgar Link	unprocessable
arwr-20230930_lab.xml	Edgar Link	unprocessable
arwr-20230930_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
arwr-20230930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

2023 Q4 Form 10-K Financial Statement

#000162828023040219 Filed on November 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARWR ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr

2023 Q4 Form 10-K Financial Statement

#000162828023040219 Filed on November 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARWR
ARROWHEAD PHARMACEUTICALS, INC. Stock $arwr